CLOs on the Move

Hilsinger Company dba Hilco USA

www.hilco.com

 
Hilsinger Company L.P. dba Hilco USA is a Plainville, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Valued Relationships (VRI)

Valued Relationships (VRI) is a Franklin, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Southwest Center

Southwest Center is a leader in providing HIV/AIDS services in Phoenix, AZ, including: HIV and STD testing, LGBTQ-friendly medical care, PrEP & PEP, community outreach, case management, behavioral health, empowerment programs, nutrition servic...

The Health Trust

The Health Trust offers a competitive and comprehensive benefits package that includes medical, dental, vision, life insurance/LTD/AD&D, flexible spending accounts, 403(b)/401(a) retirement plan, employee assistance plan and vacation and sick time

KaloBios

KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.

Huron Medical Center

Huron Medical Center is committed to providing excellence in healthcare to our communities in a caring, compassionate manner. Huron Medical Center`s vision is to be the medical center for the communities served with continuous advancement of services offered.